Humans are continually exposed to a wide variety of chemicals, some of which may act as initiators, promoters, cocarcinogens and/or complete carcinogens. Current evidence suggests that tumor promotion plays an important role in the etiology of human cancer. The proposed research is designed to investigate the mechanism of action of the anthracene-derived mouse skin tumor promoters using 1,8-dihydroxy-3-methyl-9-anthrone (chrysarobin) as the prototype. Although much is known about the mechanism of skin tumor promotion by phorbol esters, little is known about the mechanism of action of the anthracene-derived compounds.
The specific aims of the proposal are as follows. The ability of chrysarobin to interact directly or indirectly with phorbol ester bindng sites will be determined. Our preliminary data indicates that chrysarobin does not interact competitively with the phorbol ester receptor. We will examine the ability of chrysarobin to activate a partially purified protein kinase C in vitro and/our to stimulate production of 1,2-diacylglycerol in cultures of mouse epidermal cells. We will also determine the ability of chrysarobin to interact with the Ah-receptor (also called the TCDD-receptor) of mouse epidermal cells. A major emphasis will be to determine if specific, saturable receptors exist for chrysarobin. In this regard, chrysarobin will be radioactively labeled and assayed for specific binding to mouse epidermal particulate and soluble fractions and mouse epidermal cells in culture. After binding assays have been developed the affinity of other structural analogs will be determined by competition experiments. We will als determine the subcellular localization and distribution of specific binding for chrysarobin. Finally, if appropriate, we will further characterize the induction of epidermal ornithine decarboxylase by chrysarobin and its relationship to skin tumor promotion by this class of compounds. This experimental approach will allow us to further test the hypothesis that anthracene derived mouse skin tumor promoters work by a mechanism different than the phorbol esters.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA037111-04
Application #
3174804
Study Section
Chemical Pathology Study Section (CPA)
Project Start
1983-08-01
Project End
1988-07-31
Budget Start
1986-08-01
Budget End
1987-07-31
Support Year
4
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Organized Research Units
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Rho, Okkyung; Kiguchi, Kaoru; Jiang, Guiyu et al. (2014) Impact of mTORC1 inhibition on keratinocyte proliferation during skin tumor promotion in wild-type and BK5.AktWT mice. Mol Carcinog 53:871-82
Checkley, L Allyson; Rho, Okkyung; Angel, Joe M et al. (2014) Metformin inhibits skin tumor promotion in overweight and obese mice. Cancer Prev Res (Phila) 7:54-64
Hursting, Stephen D; Digiovanni, John; Dannenberg, Andrew J et al. (2012) Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev Res (Phila) 5:1260-72
Carr, Theresa D; DiGiovanni, John; Lynch, Christopher J et al. (2012) Inhibition of mTOR suppresses UVB-induced keratinocyte proliferation and survival. Cancer Prev Res (Phila) 5:1394-404
Rho, Okkyung; Kim, Dae Joon; Kiguchi, Karou et al. (2011) Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis. Mol Carcinog 50:264-79
Checkley, L Allyson; Rho, Okkyung; Moore, Tricia et al. (2011) Rapamycin is a potent inhibitor of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Cancer Prev Res (Phila) 4:1011-20
Kiguchi, Kaoru; Kitamura, Takuya; Moore, Tricia et al. (2010) Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis. Cancer Prev Res (Phila) 3:940-52
Moral, Marta; Segrelles, Carmen; Lara, M Fernanda et al. (2009) Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma. Cancer Res 69:1099-108
Hursting, Stephen D; Perkins, Susan N; Lavigne, Jackie A et al. (2009) Urothelial overexpression of insulin-like growth factor-1 increases susceptibility to p-cresidine-induced bladder carcinogenesis in transgenic mice. Mol Carcinog 48:671-7
Moral, Marta; Segrelles, Carmen; Martínez-Cruz, Ana Belén et al. (2009) Transgenic mice expressing constitutively active Akt in oral epithelium validate KLFA as a potential biomarker of head and neck squamous cell carcinoma. In Vivo 23:653-60

Showing the most recent 10 out of 58 publications